Financial Comparison: Rigel Pharmaceuticals (RIGL) vs. Its Rivals

Rigel Pharmaceuticals (NASDAQ:RIGL) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Rigel Pharmaceuticals to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28 million	$367.02 million	3.14
Rigel Pharmaceuticals Competitors	$691.14 million	$10.43 million	-10.13

Rigel Pharmaceuticals’ competitors have higher revenue, but lower earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for Rigel Pharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1	2	4	0	2.43
Rigel Pharmaceuticals Competitors	9789	15069	45339	1572	2.54

Rigel Pharmaceuticals currently has a consensus price target of $59.00, indicating a potential upside of 15.03%. As a group, “Biotechnology” companies have a potential upside of 94.40%. Given Rigel Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Rigel Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Rigel Pharmaceuticals Competitors	-9,046.59%	-199.78%	-30.61%

Volatility and Risk

Rigel Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals’ competitors have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.

Summary

Rigel Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.